国内440亿元医药市场将迎来巨震！

制药网2025-07-18

【制药网市场分析】7 月 15 日，国家组织药品联合采购办公室发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，头次对外公开集采品种遴选情况。其中，共有 55 个品种拟纳入此次集采。根据数据统计，从销售规模看，这55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，其中有11个品种销售额超10亿元。这些品种覆盖了多个治疗领域，如抗感染、抗肿瘤、抗过敏哮喘、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552455971?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-18 10:23","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552455971","market":"hk","top_or_hot":-1,"title":"国内440亿元医药市场将迎来巨震！","media":"制药网","content":"<div>\n<p>【制药网 市场分析】7 月 15 日，国家组织药品联合采购办公室发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，头次对外公开集采品种遴选情况。其中，共有 55 个品种拟纳入此次集采。根据数据统计，从销售规模看，这55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，其中有11个品种销售额超10亿元。这些品种覆盖了多个治疗领域，如抗感染、抗肿瘤、抗过敏哮喘、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810260597aa897a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国内440亿元医药市场将迎来巨震！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国内440亿元医药市场将迎来巨震！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-18 10:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810260597aa897a&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【制药网 市场分析】7 月 15 日，国家组织药品联合采购办公室发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，头次对外公开集采品种遴选情况。其中，共有 55 个品种拟纳入此次集采。根据数据统计，从销售规模看，这55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，其中有11个品种销售额超10亿元。这些品种覆盖了多个治疗领域，如抗感染、抗肿瘤、抗过敏哮喘、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810260597aa897a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YS42.EUR","symbol_name":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810260597aa897a&s=b","article_id":"2552455971","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810260597aa897a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552455971","pubTimestamp":1752805421,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"根据数据统计，从销售规模看，这55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，其中有11个品种销售额超10亿元。从企业过评情况来看，倍特药业、科伦药业、复星医药、石家庄四药、正大制药、福安药业、石药集团、齐鲁制药、新和成等企业将成为此次集采的重要力量。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","BK1515":"抗疫概念","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","BK1574":"生物医药B类股","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","01093":"石药集团","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1191":"制药","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1161":"生物科技","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","09939":"开拓药业-B","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","02196":"复星医药"},"translate_title":"The domestic 44 billion yuan pharmaceutical market will usher in a huge shock!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"09939":1,"01093":0.9,"02196":0.9},"content_text":"【制药网 市场分析】7 月 15 日，国家组织药品联合采购办公室发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，头次对外公开集采品种遴选情况。其中，共有 55 个品种拟纳入此次集采。根据数据统计，从销售规模看，这55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，其中有11个品种销售额超10亿元。这些品种覆盖了多个治疗领域，如抗感染、抗肿瘤、抗过敏哮喘、糖尿病用药、心血管用药、神经系统药物等，都是临床使用广泛、患者需求较大的药品。从企业过评情况来看，倍特药业、科伦药业、复星医药、石家庄四药、正大制药、福安药业、石药集团、齐鲁制药、新和成等企业将成为此次集采的重要力量。目前，它们分别有 16、15、15、14、13、12、12、10、10 个过评品种在列。业内表示，企业过评品种数量的多少，在一定程度上反映了其在药品研发、质量控制等方面的实力，也决定了它们在集采竞争中的优势。拥有较多过评品种的企业，能够在集采中提供更多的产品选择，增加中选的机会，进而扩大市场。数据显示，倍特药业16个过评品种中，包括9个注射剂、6个口服常释剂型及1个吸入剂，其中包括达格列净片、罗沙司他胶囊等12个品种为2024年后新获批品种。科伦药业15个过评品种中有8个注射剂、6个口服常释剂型、1个吸入剂在列，罗沙司他胶囊、富马酸福莫特罗吸入溶液、注射用维库溴铵、阿戈美拉汀片等为2025年新获批品种。国家组织药品集中采购旨在通过 “以量换价” 的方式，降低药品价格，减轻患者用药负担，同时促进医药行业的健康发展。自开展药品集采工作以来，已经取得了显著成效，大批药品价格大幅下降，患者受益明显。此次第十一批药品集采，继续聚焦临床使用成熟的 “老药”，并对采购规则进行了优化，如提高入选门槛，对企业的质量管控能力提出了更高要求。据悉，本次集采还另对68个满足集采遴选条件但未通过的原因进行公示。检索发现，药品未通过遴选的主要原因包括：“跨医保目录” 品种区分医保性质，各品规均不满足充分竞争格局；2024 年各省医药集中采购平台采购金额小于 1 亿元；未启动一致性评价，同时存在新老批件；存在专利侵权风险；重点管理的抗菌药物；以及临床使用风险高等。业内表示，“这一做法打破了以往企业对集采遴选标准的“信息壁垒”，释放出“集采遴选有标准、政策运行有逻辑”的积极信号。此次集采将进一步规范医药市场秩序，推动企业加强创新和质量提升，为患者提供更多质优价廉的药品。同时，通过明确的市场规则和竞争机制，引导企业合理定价，避免恶意竞争，促进行业的可持续发展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552455971","isCrawlerRequest":true}